We are live on ! Find out more
GKIM

GW&K Investment Management Portfolio holdings

AUM $11.3B
1-Year Est. Return 31.98%
This Fund
S&P 500
This Quarter Est. Return
+6.43%
1 Year Est. Return
+31.98%
3 Year Est. Return
+79.76%
5 Year Est. Return
+101.81%
10 Year Est. Return
+512.72%
AUM
$6.11B
AUM Growth
+$186M
Cap. Flow
-$115M
Cap. Flow %
-1.89%
Top 10 Hldgs %
13.08%
Holding
303
New
11
Increased
95
Reduced
181
Closed
15

Sector Composition

Rank Sector Weight
1 Industrials 16.06%
2 Technology 16%
3 Healthcare 13.61%
4 Financials 13.09%
5 Consumer Discretionary 11.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MIME
201
DELISTED
Mimecast Limited
MIME
$6.74M 0.11%
163,437
-2,331
-1% -$94.8K
CCMP
202
DELISTED
CMC Materials, Inc. Common Stock
CCMP
$6.42M 0.11%
59,652
-482
-0.8% -$52.9K
WWD icon
203
Woodward
WWD
$21B
$6.37M 0.1%
82,810
-461
-0.6% -$34.6K
GBT
204
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.3M 0.1%
139,312
+20,503
+17% +$934K
PLAY icon
205
Dave & Buster's
PLAY
$343M
$6.27M 0.1%
131,652
-1,077
-0.8% -$47.7K
EPAY
206
DELISTED
Bottomline Technologies Inc
EPAY
$5.94M 0.1%
119,279
+686
+0.6% +$30.6K
PTLA
207
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.87M 0.1%
155,317
+43,709
+39% +$1.67M
FORR icon
208
Forrester Research
FORR
$221M
$5.8M 0.1%
138,280
-927
-0.7% -$39.7K
ZGNX
209
DELISTED
Zogenix, Inc.
ZGNX
$5.56M 0.09%
125,697
-211
-0.2% -$8.7K
THO icon
210
Thor Industries
THO
$4.14B
$5.33M 0.09%
54,772
+229
+0.4% +$23.4K
TVTX icon
211
Travere Therapeutics
TVTX
$5.74B
$4.98M 0.08%
182,616
-9,537
-5% -$254K
ECPG icon
212
Encore Capital Group
ECPG
$2.01B
$4.88M 0.08%
133,376
-241
-0.2% -$10.1K
CUB
213
DELISTED
Cubic Corporation
CUB
$4.59M 0.08%
71,504
-2,399
-3% -$160K
FOLD
214
DELISTED
Amicus Therapeutics
FOLD
$4.59M 0.08%
293,712
-3,179
-1% -$48.1K
DY icon
215
Dycom Industries
DY
$12B
$4.34M 0.07%
45,925
-272
-0.6% -$27.8K
DOVA
216
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$4.33M 0.07%
144,699
+1,804
+1% +$49.1K
KNX icon
217
Knight Transportation
KNX
$11.2B
$4.19M 0.07%
109,674
+146
+0.1% +$6.01K
MMS icon
218
Maximus
MMS
$2.9B
$3.74M 0.06%
60,249
-221
-0.4% -$14.3K
BRKR icon
219
Bruker
BRKR
$8.58B
$3.4M 0.06%
116,946
-746
-0.6% -$22.7K
JELD icon
220
JELD-WEN Holding
JELD
$162M
$3.15M 0.05%
110,066
-1,715
-2% -$49.7K
DBVT
221
DBV Technologies
DBVT
$897M
$2.68M 0.04%
13,896
-168
-1% -$37.9K
HRTG icon
222
Heritage Insurance Holdings
HRTG
$973M
$2.63M 0.04%
158,085
+1,036
+0.7% +$17.1K
THR
223
DELISTED
Thermon Group Holdings
THR
$2.33M 0.04%
101,849
-969
-0.9% -$22.7K
ICLR icon
224
Icon
ICLR
$12.8B
$1.89M 0.03%
14,241
+300
+2% +$37.4K
ELGX
225
DELISTED
Endologix Inc
ELGX
$1.21M 0.02%
21,411
-799
-4% -$40.5K

Similar funds

GW&K Investment Management's Q2 2018 Portfolio in Review

As of Q2 2018, GW&K Investment Management held 303 positions worth $6.11B, up 3.1% from $5.92B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

GW&K Investment Management's Q2 2018 filing shows 11 new, 95 increased, 181 reduced and 15 closed positions. Its largest new stake was Amneal Pharmaceuticals: 1,956,906 shares worth $32.1M. The largest sale was Tyler Technologies, an estimated $48M.

By sector, the portfolio is most concentrated in Industrials at 16% of assets, up from 15% a quarter earlier, followed by Technology and Healthcare.

  • GW&K Investment Management's largest Q2 2018 buy was Amneal Pharmaceuticals: 1,956,906 shares worth $32.1M.
  • GW&K Investment Management added most to Pacific Premier Bancorp in Q2 2018, an estimated $17.9M increase.
  • GW&K Investment Management's biggest Q2 2018 reduction was Tyler Technologies, cutting an estimated $48M.
  • GW&K Investment Management fully exited Impax Laboratories, Inc. in Q2 2018, selling an estimated $38.5M.
  • GW&K Investment Management's ten largest holdings make up 13% of its $6.11B portfolio in Q2 2018.
  • GW&K Investment Management opened 11 new positions and closed 15 in Q2 2018.
  • GW&K Investment Management's portfolio value rose 3.1% quarter-over-quarter to $6.11B.

Based on GW&K Investment Management's 13F filing for Q2 2018, filed 7 Aug 2018.